FDA has approved perioperative pembrolizumab for resectable head and neck squamous cell carcinoma, but do patients need ...

In this video, Susana M. Campos, MD, MPH, discusses results from a phase 2 trial of pembrolizumab and lenvatinib for patients with recurrent or persistent clear-cell ovarian cancer.Findings from the ...

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the US Food and Drug Administration for the treatment of ...

The FDA has granted approval to pembrolizumab for the treatment of adult patients with resectable, locally advanced HNSCC ...

Pembrolizumab consistently improves overall and disease-free survival in clear cell renal cell carcinoma, showing sustained ...

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the ...

Alvotech and Dr. Reddy’s have entered into a collaboration and license agreement to co-develop, manufacture and commercialize ...

A grandad with advanced lung cancer which often leaves patients dead within four months has become free of the disease after ...

Alvotech and Dr. Reddy’s Enter into collaboration to co-develop biosimilar candidate to Keytruda® (pembrolizumab).

The Phase 1 dose escalation has been completed, and results show encouraging early signs of clinical activity in solid tumors ...

A new research paper was published in Volume 16 of Oncotarget on June 10, 2025, titled "Exceptional responders to ...